雪莲通脉丸治疗气虚血瘀型后循环缺血性眩晕的临床观察

The clinical research of Xuelian Tongmai Pill on posterior circulation ischemic vertigo dizziness of phlegm turbidity resistance type

[目的]观察雪莲通脉丸治疗气虚血瘀型后循环缺血性眩晕病患者的临床疗效。[方法]将120例后气虚血瘀型后循环缺血性眩晕患者随机分为治疗组和对照组,每组各60例,对照组给予尼莫地平片口服,治疗组在对照组治疗的基础上加用雪莲通脉丸口服治疗,治疗8周后分别观察两组临床疗效、血黏度及脑动脉血流指标椎动脉(VA)和基底动脉(BA)的收缩峰血流速度(Vp)、舒张峰血流速度(Vd)及平均血流速度(Vm)等指标的变化。[结果]1)治疗后治疗组眩晕症状积分明显优于对照组(P<0.05);2)治疗后观察组患者治疗总有效率93.3%显著高于对照组81.7%(P<0.01);3)治疗后治疗组血流变与对照组比较有统计学意义(P<0.05);4)两组治疗后与治疗前比较平均血流速度均有明显改善,差异具有统计学意义(P<0.05),治疗后治疗组经颅多普勒(TCD)检查椎-基底动脉平均血流速度(Vm)和血管搏动指数(PI)改善均明显优于对照组(P<0.05)。[结论]雪莲通脉丸能够改善后循环缺血性眩晕,减轻临床症状,其机制之一可能与其改变平均椎-基底动脉血流速度和血黏度有关。

[Objective]To observe the clinical efficacy of Xuelian Tongmai Pill in treating posterior circulation ischemic vertigo dizziness(phlegm turbidity resistance type).[Methods]Onehundred and twenty patients who were suffered from posterior circulation ischemic vertigo dizziness(phlegm turbidity resistance type)were randomly divided into the treatment group and the contrast group,which each group concludes 60 patients.The contrast group was treated with Nimodipine tablet,while the treatment group was treated with Nimodipine tablet and Xuelian Tongmai pill.The course of treatment was 8 weeks.The changes in syndrome score,blood flow velocity of the vertebrobasilar artery,and cerebral arteries blood flow index of vertebral artery(VA)and basilar artery(BA)systolic peak flow velocity(Vp),peak diastolic blood flow velocity(Vd)and other indicators of change were evaluated after the treatment.[Results]There was significant difference between the treatment group and the contrast group on vertigo symptom integral scores,total efficiency,TCD,Vm,PI and blood viscosity after the treatment(P<0.05).[Conclusion]XueLianTongMai Pill can not only improve the posterior circulation ischemic vertigo but also relieve symptoms of dizziness.And the mechanism may be that it can alter the average vertebral-basilar artery flow velocity and blood viscosity.